{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:57:46Z","timestamp":1792814266802,"version":"4.5.0"},"reference-count":45,"publisher":"Baishideng Publishing Group Inc.","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3748\/wjg.v20.i43.16014","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T06:17:23Z","timestamp":1457763443000},"page":"16014","source":"Crossref","is-referenced-by-count":62,"title":["Risk of infections associated with biological treatment in inflammatory bowel disease"],"prefix":"10.3748","volume":"20","author":[{"given":"Nynne Nyboe","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Jess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2005.08.011"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.11.026"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20845"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"ref10","unstructured":"Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2005;39:21-26."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-963.","DOI":"10.1093\/clinids\/11.6.954"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn&rsquo;s disease and ulcerative colitis. J Clin Gastroenterol 2003;37:220-225.","DOI":"10.1097\/00004836-200309000-00006"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.89"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163642"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.218"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1692"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2014.55.2.442"},{"key":"ref20","unstructured":"Deepak P, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-&alpha; inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2013;22:269-276."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"ref22","unstructured":"World Health Organisation (WHO). Global tuberculosis repart 2013. Geneva. WHO; 23 Oct 2013. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/91355\/9789241564656_eng.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/91355\/9789241564656_eng.pdf<\/ext-link>."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.002"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Seiderer J, G&ouml;ke B, Ochsenk&uuml;hn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 2004;70:3-9.","DOI":"10.1159\/000080075"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2405-z"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-339.","DOI":"10.1053\/j.gastro.2007.05.006"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.006"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.05.012"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21329"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02050.x"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28801"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1099"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03949.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn&rsquo;s disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002;14:1393-1395.","DOI":"10.1097\/00042737-200212000-00018"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00869.x"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.040675"},{"key":"ref41","unstructured":"Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still&rsquo;s disease. J Rheumatol 2003;30:1624-1625."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.686"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986;323:819-822.","DOI":"10.1038\/323819a0"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00812.x"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i43\/16014.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T09:46:33Z","timestamp":1567676793000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i43\/16014.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":45,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v20.i43.16014","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}